The EPS projection of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for quarter ended 2016-09-30 is $0.18. Last week, the projection for EPS was $0.18 against target of $0.18, a month earlier. While 2-months ago, this projection was $0.18 versus forecast of $0.18a quarter months earlier, posting a deviation of 0%.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 2.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 2, and 2, correspondingly.
The per-share earnings downgrade for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the preceding 30 and 120 were 1 and 2. While in 60 and 90 days were 1, and 2, in that order.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) EPS target was $0.18 for the quarter closed 1. It was based on 5 calls. As on 2016-05-03 the EPS was $0.08. The change was $0, posting a deviation of 0%. The price projections gave a standard deviation of 0.02.
Quarterly Sales Estimates
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) sales prediction for the fiscal 2016 stands at $59.615 and the median estimate is at $59.155. Almost 4 analysts gave sales target.
Among this, the highest sales estimate is $62.7 while the lowest target is $57.45 showing standard deviation of 2.373%.
As many as 4 analysts have positive sales targets revision while 4 reduced sales estimates, posting a deviation of 0%.
Last month, 4 experts have positive sales number revision. Also, 4 research groups lowered the sales projections, posting a deviation of -0.459%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast, posting a deviation of -0.778%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...